| Raggruppamenti |
Patologia |
Remissione clinica |
Migliorato |
Invariato |
Peggiorato |
Non perv. |
Deceduto |
Tot |
Neurologia
(
1478 Gruppi di Trattamenti ) |
MIASTENIA GRAVE |
41 (8.02%) |
364 (71.23%) |
63 (12.33%) |
4 (0.78%) |
39 (7.63%) |
0 (0%) |
511 |
| SINDROME MIASTENIFORME DI LAMBERT EATON |
0 (0%) |
29 (93.55%) |
2 (6.45%) |
0 (0%) |
0 (0%) |
0 (0%) |
31 |
| POLIRADICOLONEVRITE INFIAMMATORIA ACUTA (SINDROME DI GUILLAIN BARRE') |
88 (22.74%) |
198 (51.16%) |
41 (10.59%) |
13 (3.36%) |
43 (11.11%) |
4 (1.03%) |
387 |
| POLINEUROPATIA INFIAMMATORIA CRONICA CON IgG MONOCLONALI |
2 (2.94%) |
41 (60.29%) |
19 (27.94%) |
0 (0%) |
6 (8.82%) |
0 (0%) |
68 |
| POLINEUROPATIA INFIAMMATORIA CRONICA SENZA IgG MONOCLONALI |
1 (1.37%) |
43 (58.9%) |
27 (36.99%) |
1 (1.37%) |
1 (1.37%) |
0 (0%) |
73 |
| SINDROME DI MILLER FISCHER |
7 (30.43%) |
12 (52.17%) |
1 (4.35%) |
0 (0%) |
3 (13.04%) |
0 (0%) |
23 |
| AMILOIDOSI |
0 (0%) |
2 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 |
| MALATTIA DI REFSUM |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| NEUROPATIE PERIFERICHE NON SPECIFICATE |
0 (0%) |
6 (42.86%) |
7 (50%) |
0 (0%) |
1 (7.14%) |
0 (0%) |
14 |
| SCLEROSI MULTIPLA |
1 (1.82%) |
23 (41.82%) |
19 (34.55%) |
0 (0%) |
12 (21.82%) |
0 (0%) |
55 |
| ALTRE MALATTIE NEUROLOGICHE |
2 (4.55%) |
21 (47.73%) |
15 (34.09%) |
3 (6.82%) |
3 (6.82%) |
0 (0%) |
44 |
| NEUROMIOTONIA ACQUISITA |
0 (0%) |
14 (87.5%) |
0 (0%) |
0 (0%) |
2 (12.5%) |
0 (0%) |
16 |
| SCLEROSI LATERALE AMIOTROFICA |
0 (0%) |
0 (0%) |
10 (83.33%) |
0 (0%) |
2 (16.67%) |
0 (0%) |
12 |
| ENCEFALITE DI RASMUSSEN |
0 (0%) |
5 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
5 |
| ENCEFALOMIELITE ACUTA DISSEMINATA (ADEM) |
1 (9.09%) |
6 (54.55%) |
4 (36.36%) |
0 (0%) |
0 (0%) |
0 (0%) |
11 |
| MIASTENIA SIERONEGATIVA (CON ANTICORPI ANTI-MUSK) |
0 (0%) |
1 (50%) |
1 (50%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 |
| POLIRADICOLONEVRITE DEMIELINIZZANTE INFIAMMATORIA CRONICA (CIDP) |
2 (1.74%) |
53 (46.09%) |
25 (21.74%) |
4 (3.48%) |
31 (26.96%) |
0 (0%) |
115 |
| POLINEUROPATIA CON ANTICORPI ANTI-GM1 |
0 (0%) |
1 (50%) |
0 (0%) |
0 (0%) |
1 (50%) |
0 (0%) |
2 |
| POLINEUROPATIA CON ANTICORPI ANTI-MAG |
0 (0%) |
13 (31.71%) |
18 (43.9%) |
2 (4.88%) |
8 (19.51%) |
0 (0%) |
41 |
| ENCEFALITE LIMBICA (CON ANTICORPI ANTI-CANALE DEL POTASSIO) |
0 (0%) |
2 (33.33%) |
4 (66.67%) |
0 (0%) |
0 (0%) |
0 (0%) |
6 |
| NEUROMIELITE OTTICA DI DEVIC |
0 (0%) |
34 (79.07%) |
6 (13.95%) |
0 (0%) |
3 (6.98%) |
0 (0%) |
43 |
| ENCEFALOMIELITE |
0 (0%) |
2 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 |
| DEGENERAZIONE CEREBELLARE |
0 (0%) |
2 (66.67%) |
1 (33.33%) |
0 (0%) |
0 (0%) |
0 (0%) |
3 |
| ENCEFALITE LIMBICA |
0 (0%) |
1 (50%) |
1 (50%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 |
| STIFF MAN SYNDROME |
0 (0%) |
5 (38.46%) |
6 (46.15%) |
1 (7.69%) |
1 (7.69%) |
0 (0%) |
13 |
| Totale Raggruppamento |
145 |
879 |
270 |
28 |
156 |
4 |
|
|
| Raggruppamenti |
Patologia |
Remissione clinica |
Migliorato |
Invariato |
Peggiorato |
Non perv. |
Deceduto |
Tot |
Ematologia
(
1178 Gruppi di Trattamenti ) |
MIELOMA MULTIPLO / SINDROME DA IPERVISCOSITA |
2 (1.03%) |
103 (52.82%) |
58 (29.74%) |
7 (3.59%) |
24 (12.31%) |
1 (0.51%) |
195 |
| MACROGLOBULINEMIA / SINDROME DA IPERVISCOSITA' |
10 (7.09%) |
85 (60.28%) |
26 (18.44%) |
5 (3.55%) |
13 (9.22%) |
2 (1.42%) |
141 |
| LEUCEMIA LINFOIDE CRONICA |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| ALTRE EMOPATIE MALIGNE CON Ig MONOCLONALI |
0 (0%) |
4 (33.33%) |
3 (25%) |
3 (25%) |
2 (16.67%) |
0 (0%) |
12 |
| Ig + ALTRE MANIFESTAZIONI CLINICHE O METABOLICHE |
0 (0%) |
1 (33.33%) |
0 (0%) |
0 (0%) |
2 (66.67%) |
0 (0%) |
3 |
| EMOFILIA CON INIBITORI DELLA COAGULAZIONE |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| INCOMPATIBILITA' ABO IN CORSO DI ALLOTRAPIANTO |
1 (5.56%) |
13 (72.22%) |
1 (5.56%) |
0 (0%) |
3 (16.67%) |
0 (0%) |
18 |
| PORPORA POST-TRASFUSIONALE |
0 (0%) |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| CRISI EMOLITICA POST TRASFUSIONALE |
2 (40%) |
0 (0%) |
2 (40%) |
1 (20%) |
0 (0%) |
0 (0%) |
5 |
| APLASIA MIDOLLARE |
0 (0%) |
0 (0%) |
0 (0%) |
2 (66.67%) |
1 (33.33%) |
0 (0%) |
3 |
| NEUTROPENIA |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| PORPORA TROMBOCITOPENICA IDIOPATICA |
12 (41.38%) |
8 (27.59%) |
4 (13.79%) |
2 (6.9%) |
2 (6.9%) |
1 (3.45%) |
29 |
| ANEMIA EMOLITICA AUTOIMMUNE |
2 (6.45%) |
9 (29.03%) |
8 (25.81%) |
1 (3.23%) |
10 (32.26%) |
1 (3.23%) |
31 |
| SINDROME DA ANTICORPI ANTI-FOSFOLIPIDI CATASTROFICA |
7 (53.85%) |
3 (23.08%) |
2 (15.38%) |
0 (0%) |
1 (7.69%) |
0 (0%) |
13 |
| Poliglobulia |
0 (0%) |
108 (96.43%) |
2 (1.79%) |
0 (0%) |
2 (1.79%) |
0 (0%) |
112 |
| ALTRE MALATTIE EMATOLOGICHE |
8 (5.1%) |
130 (82.8%) |
14 (8.92%) |
1 (0.64%) |
3 (1.91%) |
1 (0.64%) |
157 |
| SINDROME UREMICA-EMOLITICA |
10 (22.22%) |
21 (46.67%) |
5 (11.11%) |
3 (6.67%) |
6 (13.33%) |
0 (0%) |
45 |
| PORPORA TROMBOTICA TROMBOCITOPENICA |
111 (46.84%) |
59 (24.89%) |
27 (11.39%) |
9 (3.8%) |
25 (10.55%) |
6 (2.53%) |
237 |
| LEUCOCITOSI (CITOAFERESI RIDUTTIVA) |
0 (0%) |
13 (61.9%) |
4 (19.05%) |
1 (4.76%) |
1 (4.76%) |
2 (9.52%) |
21 |
| TROMBOCITOSI (CITOAFERESI RIDUTTIVA) |
0 (0%) |
5 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
5 |
| DREPANOCITOSI |
60 (37.27%) |
84 (52.17%) |
5 (3.11%) |
0 (0%) |
12 (7.45%) |
0 (0%) |
161 |
| Totale Raggruppamento |
225 |
649 |
162 |
35 |
107 |
14 |
|
|
| Raggruppamenti |
Patologia |
Remissione clinica |
Migliorato |
Invariato |
Peggiorato |
Non perv. |
Deceduto |
Tot |
Nefrologia
(
398 Gruppi di Trattamenti ) |
AMILOIDOSI |
0 (0%) |
1 (25%) |
2 (50%) |
1 (25%) |
0 (0%) |
0 (0%) |
4 |
| GLOMERULONEFRITE A DEPOSITI MESANGIALI DI IgA |
0 (0%) |
2 (13.33%) |
7 (46.67%) |
3 (20%) |
3 (20%) |
0 (0%) |
15 |
| SINDROME DI GOODPASTURE |
3 (15.79%) |
4 (21.05%) |
6 (31.58%) |
2 (10.53%) |
4 (21.05%) |
0 (0%) |
19 |
| GLOMERULONEFRITI PRIMITIVE NON SPECIFICATE |
2 (4.88%) |
16 (39.02%) |
16 (39.02%) |
2 (4.88%) |
5 (12.2%) |
0 (0%) |
41 |
| GLOMERULOPATIE SECONDARIE NON SPECIFICATE |
0 (0%) |
0 (0%) |
2 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 |
| GLOMERULOPATIA DA TRAPIANTO RENALE |
2 (8.33%) |
17 (70.83%) |
2 (8.33%) |
0 (0%) |
3 (12.5%) |
0 (0%) |
24 |
| GLOMERULOSCLEROSI FOCALE E SEGMENTALE |
5 (4.72%) |
49 (46.23%) |
49 (46.23%) |
0 (0%) |
3 (2.83%) |
0 (0%) |
106 |
| GLOMERULONEFRITE MEMBRANOPROLIFERATIVA |
2 (20%) |
4 (40%) |
3 (30%) |
0 (0%) |
1 (10%) |
0 (0%) |
10 |
| GLOMERULONEFRITE RAPIDAMENTE PROGRESSIVA (NON ANCA ASSOCIATA) |
3 (5.56%) |
24 (44.44%) |
19 (35.19%) |
3 (5.56%) |
5 (9.26%) |
0 (0%) |
54 |
| GLOMERULONEFRITE MEMBRANOSA |
0 (0%) |
14 (73.68%) |
5 (26.32%) |
0 (0%) |
0 (0%) |
0 (0%) |
19 |
| IALINOSI FOCALE |
0 (0%) |
1 (33.33%) |
2 (66.67%) |
0 (0%) |
0 (0%) |
0 (0%) |
3 |
| RECIDIVA DI GLOMERULOSCLEROSI FOCALE E SEGMENTALE |
1 (2.94%) |
25 (73.53%) |
7 (20.59%) |
1 (2.94%) |
0 (0%) |
0 (0%) |
34 |
| RECIDIVA DI GLOMERULONEFRITE PRIMITIVA |
3 (27.27%) |
7 (63.64%) |
1 (9.09%) |
0 (0%) |
0 (0%) |
0 (0%) |
11 |
| ALTRE GLOMERULOPATIE |
1 (7.14%) |
9 (64.29%) |
2 (14.29%) |
0 (0%) |
2 (14.29%) |
0 (0%) |
14 |
| PREVENZIONE DELLA RECIDIVA DI GLOMERULOSCLEROSI FOCALE E SEGMENTALE |
0 (0%) |
12 (85.71%) |
2 (14.29%) |
0 (0%) |
0 (0%) |
0 (0%) |
14 |
| GLOMERULONEFRITE DI NUOVA INSORGENZA |
0 (0%) |
4 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
4 |
| GNRP VASCULITE LIMITATA RENALE (ANCA ASSOCIATA) |
3 (15%) |
9 (45%) |
4 (20%) |
0 (0%) |
4 (20%) |
0 (0%) |
20 |
| MALATTIA A CATENE LEGGERE |
0 (0%) |
1 (33.33%) |
2 (66.67%) |
0 (0%) |
0 (0%) |
0 (0%) |
3 |
| GLOMERULONEFRITE MESANGIALE PROLIFERATIVA NON IgA |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| Totale Raggruppamento |
25 |
200 |
131 |
12 |
30 |
0 |
|
|
| Raggruppamenti |
Patologia |
Remissione clinica |
Migliorato |
Invariato |
Peggiorato |
Non perv. |
Deceduto |
Tot |
Dermatologia
(
31 Gruppi di Trattamenti ) |
PEMFIGO BOLLOSO |
2 (25%) |
4 (50%) |
1 (12.5%) |
0 (0%) |
1 (12.5%) |
0 (0%) |
8 |
| PEMFIGO |
1 (16.67%) |
2 (33.33%) |
1 (16.67%) |
1 (16.67%) |
1 (16.67%) |
0 (0%) |
6 |
| PSORIASI |
0 (0%) |
0 (0%) |
3 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
3 |
| PORFIRIE |
0 (0%) |
4 (80%) |
0 (0%) |
0 (0%) |
1 (20%) |
0 (0%) |
5 |
| ALTRE MALATTIE DERMATOLOGICHE |
1 (10%) |
1 (10%) |
2 (20%) |
0 (0%) |
5 (50%) |
1 (10%) |
10 |
| Totale Raggruppamento |
4 |
11 |
7 |
1 |
8 |
1 |
|
|
| Raggruppamenti |
Patologia |
Remissione clinica |
Migliorato |
Invariato |
Peggiorato |
Non perv. |
Deceduto |
Tot |
Vasculiti e malattie sistemiche
(
1152 Gruppi di Trattamenti ) |
LUPUS ERITEMATOSO SISTEMICO |
59 (17.1%) |
137 (39.71%) |
124 (35.94%) |
11 (3.19%) |
14 (4.06%) |
0 (0%) |
345 |
| PERIARTERITE / POLIARTRITE NODOSA |
0 (0%) |
2 (50%) |
2 (50%) |
0 (0%) |
0 (0%) |
0 (0%) |
4 |
| GRANULOMATOSI DI WEGENER |
6 (7.59%) |
48 (60.76%) |
16 (20.25%) |
3 (3.8%) |
6 (7.59%) |
0 (0%) |
79 |
| MALATTIA DI BEHCET |
0 (0%) |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| ARTRITE REUMATOIDE |
2 (4.88%) |
27 (65.85%) |
7 (17.07%) |
1 (2.44%) |
4 (9.76%) |
0 (0%) |
41 |
| SCLERODERMIA |
1 (1.89%) |
26 (49.06%) |
21 (39.62%) |
3 (5.66%) |
2 (3.77%) |
0 (0%) |
53 |
| DERMATOPOLIMIOSITE |
6 (16.67%) |
22 (61.11%) |
5 (13.89%) |
0 (0%) |
3 (8.33%) |
0 (0%) |
36 |
| PORPORA REUMATOIDE |
0 (0%) |
0 (0%) |
1 (50%) |
0 (0%) |
1 (50%) |
0 (0%) |
2 |
| MALATTIA DA SIERO |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| MALATTIA DI CHURG E STRAUSS |
0 (0%) |
2 (33.33%) |
2 (33.33%) |
0 (0%) |
2 (33.33%) |
0 (0%) |
6 |
| VASCULITI ANCA CORRELATE |
6 (12.5%) |
26 (54.17%) |
14 (29.17%) |
1 (2.08%) |
1 (2.08%) |
0 (0%) |
48 |
| VASCULITI NON SPECIFICATE |
2 (3.51%) |
29 (50.88%) |
16 (28.07%) |
2 (3.51%) |
8 (14.04%) |
0 (0%) |
57 |
| MALATTIE REUMATICHE NON SPECIFICATE |
0 (0%) |
1 (50%) |
1 (50%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 |
| MALATTIA DI SCHOENLEIN HENOCH |
0 (0%) |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| MICROPOLIARTERITE |
0 (0%) |
1 (50%) |
1 (50%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 |
| VASCULITI O MALATTIE REUMATICHE NON SPECIFICATE |
0 (0%) |
6 (46.15%) |
2 (15.38%) |
3 (23.08%) |
2 (15.38%) |
0 (0%) |
13 |
| SINDROME DA ANTIFOSFOLIPIDI |
0 (0%) |
2 (40%) |
2 (40%) |
0 (0%) |
0 (0%) |
1 (20%) |
5 |
| CRIOGLOBULINEMIA TIPO 1-2-3 |
20 (5.13%) |
272 (69.74%) |
60 (15.38%) |
18 (4.62%) |
20 (5.13%) |
0 (0%) |
390 |
| CRIOGLOBULINEMIA HCV POSITIVA |
2 (3.51%) |
34 (59.65%) |
9 (15.79%) |
0 (0%) |
12 (21.05%) |
0 (0%) |
57 |
| CRIOGLOBULINEMIA HCV NEGATIVA |
0 (0%) |
9 (90%) |
0 (0%) |
1 (10%) |
0 (0%) |
0 (0%) |
10 |
| Totale Raggruppamento |
105 |
644 |
285 |
43 |
75 |
1 |
|
|
| Raggruppamenti |
Patologia |
Remissione clinica |
Migliorato |
Invariato |
Peggiorato |
Non perv. |
Deceduto |
Tot |
Endocrinologia - Metabolismo
(
767 Gruppi di Trattamenti ) |
IPERTIROIDISMO / TIREOTOSSICOSI |
0 (0%) |
14 (87.5%) |
2 (12.5%) |
0 (0%) |
0 (0%) |
0 (0%) |
16 |
| DIABETE |
0 (0%) |
0 (0%) |
3 (75%) |
0 (0%) |
1 (25%) |
0 (0%) |
4 |
| IPERCOLESTEROLEMIA NON DEFINITA |
2 (3.64%) |
26 (47.27%) |
21 (38.18%) |
1 (1.82%) |
5 (9.09%) |
0 (0%) |
55 |
| IPERCOLESTEROLEMIA FAMILIARE OMOZIGOTE |
5 (7.04%) |
50 (70.42%) |
12 (16.9%) |
0 (0%) |
4 (5.63%) |
0 (0%) |
71 |
| IPERCOLESTEROLEMIA FAMILIARE ETEROZIGOTE REFRATTARIA A TERAPIA |
8 (4.49%) |
125 (70.22%) |
37 (20.79%) |
0 (0%) |
8 (4.49%) |
0 (0%) |
178 |
| IPERCOLESTEROLEMIA FAMILIARE DOPPIO ETEROZIGOTE O COMPOUND |
0 (0%) |
23 (26.14%) |
62 (70.45%) |
1 (1.14%) |
2 (2.27%) |
0 (0%) |
88 |
| IPERTRIGLICERIDEMIA REFRATTARIA A TERAPIA |
3 (23.08%) |
9 (69.23%) |
0 (0%) |
1 (7.69%) |
0 (0%) |
0 (0%) |
13 |
| ESOFTALMO |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| ALTRE MALATTIE ENDOCRINE O METABOLICHE |
0 (0%) |
9 (81.82%) |
2 (18.18%) |
0 (0%) |
0 (0%) |
0 (0%) |
11 |
| IPERCOLESTEROLEMIA FAMILIARE AUTOSOMICA RECESSIVA |
10 (5.65%) |
135 (76.27%) |
30 (16.95%) |
1 (0.56%) |
1 (0.56%) |
0 (0%) |
177 |
| IPERCOLESTEROLEMIA FAMILIARE ETEROZIGOTE CON ALTERAZIONE STRUTTURALE DELLA APO B |
2 (22.22%) |
7 (77.78%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
9 |
| IPER-Lp(a)LIPOPROTEINEMIA |
0 (0%) |
42 (93.33%) |
3 (6.67%) |
0 (0%) |
0 (0%) |
0 (0%) |
45 |
| IPERCOLESTEROLEMIA NELLE MALATTIE RENALI REFRATTARIA A TERAPIA |
0 (0%) |
1 (50%) |
1 (50%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 |
| IPERCOLESTEROLEMIA IN PORTATORI DI TRAPIANTO CARDIACO |
7 (21.21%) |
17 (51.52%) |
9 (27.27%) |
0 (0%) |
0 (0%) |
0 (0%) |
33 |
| IPERCOLESTEROLEMIA IN SOTTOPOSTI A BY-PASS A-C O ACPT REFRATTARIA A TERAPIA |
0 (0%) |
23 (88.46%) |
3 (11.54%) |
0 (0%) |
0 (0%) |
0 (0%) |
26 |
| ALTRE IPERLIPOPROTEINEMIA ED IPERTRIGLICERIDEMIA |
0 (0%) |
9 (52.94%) |
6 (35.29%) |
0 (0%) |
2 (11.76%) |
0 (0%) |
17 |
| IPERTRIGLICERIDEMIA FAMILIARE (TIPO IV) |
0 (0%) |
2 (66.67%) |
1 (33.33%) |
0 (0%) |
0 (0%) |
0 (0%) |
3 |
| IPERTRIGLICERIDEMIA FAMILIARE (TIPO V) |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| IPERLIPIDEMIA FAMILIARE COMBINATA |
4 (23.53%) |
10 (58.82%) |
3 (17.65%) |
0 (0%) |
0 (0%) |
0 (0%) |
17 |
| Totale Raggruppamento |
41 |
504 |
195 |
4 |
23 |
0 |
|
|
| Raggruppamenti |
Patologia |
Remissione clinica |
Migliorato |
Invariato |
Peggiorato |
Non perv. |
Deceduto |
Tot |
Malattie digestive
(
813 Gruppi di Trattamenti ) |
EPATOPATIA DA FARMACI (COLESTASI SEVERA / ITTERO) |
4 (25%) |
11 (68.75%) |
0 (0%) |
1 (6.25%) |
0 (0%) |
0 (0%) |
16 |
| CIRROSI BILIARE PRIMITIVA (COLESTASI SEVERA/ITTERO) |
3 (5.88%) |
34 (66.67%) |
7 (13.73%) |
4 (7.84%) |
3 (5.88%) |
0 (0%) |
51 |
| ALTRE MALATTIE EPATICHE (COLESTASI SEVERA / ITTERO) |
7 (9.59%) |
40 (54.79%) |
16 (21.92%) |
7 (9.59%) |
2 (2.74%) |
1 (1.37%) |
73 |
| MALATTIA DI CROHN |
13 (23.64%) |
15 (27.27%) |
16 (29.09%) |
4 (7.27%) |
7 (12.73%) |
0 (0%) |
55 |
| ALTRE MALATTIE DEL DIGERENTE |
0 (0%) |
3 (75%) |
1 (25%) |
0 (0%) |
0 (0%) |
0 (0%) |
4 |
| IPERBILIRUBINEMIA / ITTERO |
19 (17.43%) |
57 (52.29%) |
27 (24.77%) |
6 (5.5%) |
0 (0%) |
0 (0%) |
109 |
| CIRROSI ALCOOLICA (COLESTASI SEVERA/ITTERO) |
0 (0%) |
17 (53.13%) |
10 (31.25%) |
5 (15.63%) |
0 (0%) |
0 (0%) |
32 |
| CIRROSI EPATICA (NON SPECIFICATA) |
0 (0%) |
2 (40%) |
3 (60%) |
0 (0%) |
0 (0%) |
0 (0%) |
5 |
| EPATITE ACUTA FULMINANTE DI ORIGINE VIRALE |
0 (0%) |
8 (47.06%) |
7 (41.18%) |
1 (5.88%) |
0 (0%) |
1 (5.88%) |
17 |
| EPATOCARCINOMA |
0 (0%) |
2 (20%) |
6 (60%) |
1 (10%) |
1 (10%) |
0 (0%) |
10 |
| COLANGIOCARCINOMA |
0 (0%) |
2 (66.67%) |
0 (0%) |
1 (33.33%) |
0 (0%) |
0 (0%) |
3 |
| EPATITE ACUTA DA HAV |
0 (0%) |
1 (50%) |
1 (50%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 |
| CIRROSI EPATICA DA HCV (COLESTASI SEVERA/ITTERO) |
1 (2.78%) |
20 (55.56%) |
11 (30.56%) |
4 (11.11%) |
0 (0%) |
0 (0%) |
36 |
| CIRROSI EPATICA DA HBV (COLESTASI SEVERA/ITTERO) |
0 (0%) |
4 (50%) |
2 (25%) |
1 (12.5%) |
1 (12.5%) |
0 (0%) |
8 |
| COLANGITE SCLEROSANTE PRIMITIVA |
0 (0%) |
2 (66.67%) |
0 (0%) |
1 (33.33%) |
0 (0%) |
0 (0%) |
3 |
| INSUFFICIENZA EPATICA ACUTA DA FARMACI |
0 (0%) |
6 (54.55%) |
3 (27.27%) |
1 (9.09%) |
1 (9.09%) |
0 (0%) |
11 |
| EPATOPATIA DA AVVELENAMENTO DA SOSTANZE TOSSICHE |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| EPATITE ACUTA ALCOOLICA |
0 (0%) |
3 (42.86%) |
3 (42.86%) |
1 (14.29%) |
0 (0%) |
0 (0%) |
7 |
| EPATITE ACUTA DA HBV |
0 (0%) |
6 (66.67%) |
2 (22.22%) |
0 (0%) |
0 (0%) |
1 (11.11%) |
9 |
| EPATITE ACUTA DA ALTRI VIRUS |
0 (0%) |
2 (50%) |
2 (50%) |
0 (0%) |
0 (0%) |
0 (0%) |
4 |
| ALTRE MALATTIE EPATICHE (INSUFFICIENZA EPATICA ACUTA) |
0 (0%) |
6 (85.71%) |
0 (0%) |
1 (14.29%) |
0 (0%) |
0 (0%) |
7 |
| CIRROSI EPATICA DA HBV (COMA EPATICO) |
0 (0%) |
1 (50%) |
1 (50%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 |
| CIRROSI EPATICA DA HCV (COMA EPATICO) |
0 (0%) |
7 (87.5%) |
0 (0%) |
1 (12.5%) |
0 (0%) |
0 (0%) |
8 |
| CIRROSI ALCOOLICA (COMA EPATICO) |
0 (0%) |
2 (40%) |
2 (40%) |
1 (20%) |
0 (0%) |
0 (0%) |
5 |
| CIRROSI BILIARE PRIMITIVA (COMA EPATICO) |
0 (0%) |
1 (33.33%) |
1 (33.33%) |
1 (33.33%) |
0 (0%) |
0 (0%) |
3 |
| RETTOCOLITE ULCEROSA |
102 (31.38%) |
102 (31.38%) |
73 (22.46%) |
9 (2.77%) |
39 (12%) |
0 (0%) |
325 |
| COLITE INDETERMINATA |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 (100%) |
0 (0%) |
1 |
| COLESTASI FAMILIARE |
2 (66.67%) |
1 (33.33%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
3 |
| SINDROME EPATORENALE |
0 (0%) |
3 (50%) |
3 (50%) |
0 (0%) |
0 (0%) |
0 (0%) |
6 |
| Totale Raggruppamento |
151 |
359 |
197 |
51 |
55 |
3 |
|
|
| Raggruppamenti |
Patologia |
Remissione clinica |
Migliorato |
Invariato |
Peggiorato |
Non perv. |
Deceduto |
Tot |
Malattie del microcircolo
(
147 Gruppi di Trattamenti ) |
NEUROPATIA ISCHEMICA DEL NERVO OTTICO |
2 (5.13%) |
31 (79.49%) |
5 (12.82%) |
1 (2.56%) |
0 (0%) |
0 (0%) |
39 |
| MACULOPATIA DEGENERATIVA SENILE |
0 (0%) |
18 (90%) |
2 (10%) |
0 (0%) |
0 (0%) |
0 (0%) |
20 |
| VASCULOPATIA ARTI INFERIORI |
5 (13.51%) |
25 (67.57%) |
7 (18.92%) |
0 (0%) |
0 (0%) |
0 (0%) |
37 |
| SORDITA' IMPROVVISA |
6 (13.04%) |
26 (56.52%) |
10 (21.74%) |
0 (0%) |
4 (8.7%) |
0 (0%) |
46 |
| ALTRE MALATTIE DEL MICROCIRCOLO |
0 (0%) |
2 (66.67%) |
1 (33.33%) |
0 (0%) |
0 (0%) |
0 (0%) |
3 |
| STROKE |
0 (0%) |
2 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 |
| Totale Raggruppamento |
13 |
104 |
25 |
1 |
4 |
0 |
|
|
| Raggruppamenti |
Patologia |
Remissione clinica |
Migliorato |
Invariato |
Peggiorato |
Non perv. |
Deceduto |
Tot |
Oncologia
(
84 Gruppi di Trattamenti ) |
ALTRE NEOPLASIE |
0 (0%) |
24 (42.11%) |
29 (50.88%) |
1 (1.75%) |
3 (5.26%) |
0 (0%) |
57 |
| LINFOMA CUTANEO A CELLULE T/ERITRODERMIA |
3 (13.04%) |
14 (60.87%) |
4 (17.39%) |
2 (8.7%) |
0 (0%) |
0 (0%) |
23 |
| SINDROME PARANEOPLASTICA |
0 (0%) |
1 (50%) |
0 (0%) |
1 (50%) |
0 (0%) |
0 (0%) |
2 |
| TUMORI NEUROENDOCRINI |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| LEUCEMIA LINFOBLASTICA ACUTA |
0 (0%) |
0 (0%) |
1 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 |
| Totale Raggruppamento |
3 |
40 |
34 |
4 |
3 |
0 |
|
|
| Raggruppamenti |
Patologia |
Remissione clinica |
Migliorato |
Invariato |
Peggiorato |
Non perv. |
Deceduto |
Tot |
Trapianti
(
277 Gruppi di Trattamenti ) |
RIGETTO DI RENE ANTICORPO MEDIATO |
16 (17.2%) |
34 (36.56%) |
23 (24.73%) |
4 (4.3%) |
16 (17.2%) |
0 (0%) |
93 |
| DESENSIBILIZZAZIONE PER TX RENE DA DONATORE VIVENTE |
0 (0%) |
2 (50%) |
1 (25%) |
0 (0%) |
1 (25%) |
0 (0%) |
4 |
| DESENSIBILIZZAZIONE PER TX RENE DA DONATORE CADAVERE |
1 (33.33%) |
0 (0%) |
2 (66.67%) |
0 (0%) |
0 (0%) |
0 (0%) |
3 |
| RIGETTO TRAPIANTO DI FEGATO |
1 (25%) |
0 (0%) |
3 (75%) |
0 (0%) |
0 (0%) |
0 (0%) |
4 |
| TRAPIANTO CELLULE STAMINALI ABO INCOMPATIBILE |
0 (0%) |
13 (81.25%) |
0 (0%) |
0 (0%) |
3 (18.75%) |
0 (0%) |
16 |
| GRAFT VERSUS HOST DISEASE ACUTO |
1 (2.7%) |
21 (56.76%) |
12 (32.43%) |
1 (2.7%) |
1 (2.7%) |
1 (2.7%) |
37 |
| GRAFT VERSUS HOST DISEASE CRONICO |
4 (4.04%) |
67 (67.68%) |
15 (15.15%) |
2 (2.02%) |
10 (10.1%) |
1 (1.01%) |
99 |
| COLESTASI SEVERA / ITTERO |
0 (0%) |
2 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 |
| PRIMARY NON-FUNCTION DOPO TRAPIANTO DI FEGATO |
0 (0%) |
3 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
3 |
| RIGETTO TRAPIANTO DI CUORE |
0 (0%) |
5 (55.56%) |
3 (33.33%) |
0 (0%) |
1 (11.11%) |
0 (0%) |
9 |
| RIGETTO NEL TRAPIANTO DI POLMONE |
0 (0%) |
0 (0%) |
6 (100%) |
0 (0%) |
0 (0%) |
0 (0%) |
6 |
| GRAFT VERSUS HOST DISEASE |
0 (0%) |
1 (33.33%) |
2 (66.67%) |
0 (0%) |
0 (0%) |
0 (0%) |
3 |
| Totale Raggruppamento |
23 |
148 |
67 |
7 |
32 |
2 |
|
|
| Raggruppamenti |
Patologia |
Remissione clinica |
Migliorato |
Invariato |
Peggiorato |
Non perv. |
Deceduto |
Tot |
Raccolta di cellule staminali
(
1067 Gruppi di Trattamenti ) |
LINFOMA NON HODGKIN (Autotrapianto) |
3 (0.83%) |
69 (19.11%) |
155 (42.94%) |
1 (0.28%) |
132 (36.57%) |
1 (0.28%) |
361 |
| MIELOMA (Allotrapianto) |
0 (0%) |
1 (10%) |
2 (20%) |
0 (0%) |
7 (70%) |
0 (0%) |
10 |
| LEUCEMIA (Allotrapianto) |
1 (1.22%) |
13 (15.85%) |
42 (51.22%) |
0 (0%) |
26 (31.71%) |
0 (0%) |
82 |
| LINFOMA NON HODGKIN (Allotrapianto) |
0 (0%) |
5 (21.74%) |
5 (21.74%) |
0 (0%) |
13 (56.52%) |
0 (0%) |
23 |
| LINFOMA DI HODGKIN (Allotrapianto) |
0 (0%) |
3 (37.5%) |
1 (12.5%) |
0 (0%) |
4 (50%) |
0 (0%) |
8 |
| MIELOMA (Autotrapianto) |
4 (1.47%) |
50 (18.38%) |
110 (40.44%) |
2 (0.74%) |
106 (38.97%) |
0 (0%) |
272 |
| LINFOMA DI HODGKIN (Autotrapianto) |
8 (6.35%) |
36 (28.57%) |
45 (35.71%) |
1 (0.79%) |
36 (28.57%) |
0 (0%) |
126 |
| LEUCEMIA (Autotrapianto) |
3 (2%) |
37 (24.67%) |
63 (42%) |
2 (1.33%) |
44 (29.33%) |
1 (0.67%) |
150 |
| NEUROBLASTOMA |
0 (0%) |
3 (75%) |
1 (25%) |
0 (0%) |
0 (0%) |
0 (0%) |
4 |
| MALATTIA AUTOIMMUNE |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
2 (100%) |
0 (0%) |
2 |
| ALTRI TUMORI SOLIDI |
0 (0%) |
8 (38.1%) |
11 (52.38%) |
0 (0%) |
2 (9.52%) |
0 (0%) |
21 |
| RACCOLTA CELLULE STAMINALI PERIFERICHE PER AUTO TRAPIANTO |
1 (10%) |
7 (70%) |
2 (20%) |
0 (0%) |
0 (0%) |
0 (0%) |
10 |
| Totale Raggruppamento |
20 |
232 |
437 |
6 |
372 |
2 |
|
|
| Raggruppamenti |
Patologia |
Remissione clinica |
Migliorato |
Invariato |
Peggiorato |
Non perv. |
Deceduto |
Tot |
Varie
(
219 Gruppi di Trattamenti ) |
ALTRE MALATTIE |
0 (0%) |
5 (71.43%) |
2 (28.57%) |
0 (0%) |
0 (0%) |
0 (0%) |
7 |
| ALTRE MALATTIE IN AREA CRITICA |
0 (0%) |
6 (85.71%) |
0 (0%) |
0 (0%) |
1 (14.29%) |
0 (0%) |
7 |
| INTOSSICAZIONI DA FARMACI |
2 (16.67%) |
5 (41.67%) |
2 (16.67%) |
1 (8.33%) |
2 (16.67%) |
0 (0%) |
12 |
| INTOSSICAZIONI DA ALTRE SOSTANZE |
0 (0%) |
3 (33.33%) |
1 (11.11%) |
0 (0%) |
5 (55.56%) |
0 (0%) |
9 |
| RABDOMIOLISI |
4 (26.67%) |
8 (53.33%) |
2 (13.33%) |
0 (0%) |
1 (6.67%) |
0 (0%) |
15 |
| ALTRE INDICAZIONI |
8 (5.52%) |
76 (52.41%) |
48 (33.1%) |
7 (4.83%) |
6 (4.14%) |
0 (0%) |
145 |
| SHOCK SETTICO |
2 (11.11%) |
8 (44.44%) |
7 (38.89%) |
1 (5.56%) |
0 (0%) |
0 (0%) |
18 |
| MULTIPLE ORGAN FAILURE |
0 (0%) |
1 (16.67%) |
4 (66.67%) |
1 (16.67%) |
0 (0%) |
0 (0%) |
6 |
| Totale Raggruppamento |
16 |
112 |
66 |
10 |
15 |
0 |
|
|
| TOTALE |
771 |
3882 |
1876 |
202 |
880 |
27 |
7628 |
| Dati soggetti a variazioni in base a nuovi inserimenti o correzioni |